Policymakers and regulatory agencies are increasingly pushing for more public access to clinical trial information. Requiring clinical trial sponsors to be more transparent about their findings would provide greater accountability and discourage unethical trial practices, suppression or selective reporting of results, or misleading analyses. Data sharing would also prevent unnecessary duplication of studies. However, disclosing clinical trial data also risks compromising the privacy of trial participants. Moreover, making a sponsor’s trial data freely available could give unfair advantages to competitors, who could potentially use the data without incurring the cost of producing it. This may discourage companies from performing trials altogether. Clinical trial data sharing therefore needs to incorporate reasonable safeguards for participant privacy and companies’ intellectual property.